Tisdag 12 Maj | 15:19:56 Europe / Stockholm

Svenska | English

Oculis Holding

Filter

År

Typ

Språk

Rensa

2026-05-11 22:07:00 Oculis Reports Q1 2026 Financial Results and Provides Company Update

2026-05-07 11:00:00 Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial 3820,00 ISK | +9,14% | 502 MISK

2026-05-07 10:57:37 Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial 3820,00 ISK | +9,14% | 502 MISK

2026-05-05 10:00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting 3520,00 ISK | +2,03% | 349 MISK

2026-05-01 10:00:00 Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

2026-04-21 22:05:00 Oculis birtir boð á aðalfund 3420,00 ISK | +0,29% | 71,4 MISK

2026-04-21 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 3420,00 ISK | +0,29% | 71,4 MISK

2026-04-20 10:00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema 3520,00 ISK | +5,71% | 454 MISK

2026-04-20 10:00:00 Oculis lýkur síðustu eftirfylgniheimsókn í fasa 3 DIAMOND rannsóknaráætluninni með OCS-01 augndropum til meðferðar á sjónhimnubjúg af völdum sykursýki 3520,00 ISK | +5,71% | 454 MISK

2026-04-20 10:00:00 Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema 3520,00 ISK | +5,71% | 454 MISK

2026-04-08 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3370,00 ISK | 0,00% | 0,63 MISK

2026-04-07 10:00:00 Oculis to Participate in Upcoming Investor Conferences 3290,00 ISK | -4,36% | 23,1 MISK

2026-03-31 11:00:00 Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis 3305,00 ISK | +7,31% | 115 MISK

2026-03-31 10:00:00 Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis 3305,00 ISK | +7,31% | 115 MISK

2026-03-27 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-03-16 10:00:00 Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting 3250,00 ISK | -2,55% | 12,3 MISK

2026-03-16 08:24:05 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3250,00 ISK | -2,55% | 12,3 MISK

2026-03-13 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-03-11 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3330,00 ISK | -4,58% | 32,6 MISK

2026-03-06 22:01:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-03-05 10:00:00 Oculis to Participate in Upcoming Investor Conferences 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-05 10:00:00 Oculis Publishes 2025 Consolidated Financial Statements 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-05 10:00:00 Oculis to Participate in Upcoming Investor Conferences 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-04 22:15:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-03 22:05:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir áfanga í rekstri félagsins 3510,00 ISK | +3,54% | 96,7 MISK

2026-03-03 22:05:00 Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update 3510,00 ISK | +3,54% | 96,7 MISK

2026-02-27 22:15:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-02-18 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 3500,00 ISK | -0,85% | 71,7 MISK

2026-02-17 10:00:00 Oculis Appoints Katie Kazem as Chief Legal Officer 3530,00 ISK | +1,73% | 291 MISK

2026-01-08 10:00:00 Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference 2790,00 ISK | +4,49% | 453 MISK

2026-01-06 10:00:00 Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis 2770,00 ISK | +10,36% | 525 MISK

2026-01-06 10:00:00 Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu 2770,00 ISK | +10,36% | 525 MISK

2026-01-06 10:00:00 Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis 2770,00 ISK | +10,36% | 525 MISK

2025-12-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2650,00 ISK | -1,49% | 5,64 MISK

2025-12-03 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2460,00 ISK | +2,50% | 69,4 MISK

2025-11-28 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2025-11-18 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2450,00 ISK | +1,24% | 13,2 MISK

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-05 10:00:00 Oculis to Participate in Upcoming November Investor Conferences 2450,00 ISK | +1,03% | 45,4 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden